Hexarelin

What Hexarelin does

Hexarelin releases growth hormone and can raise prolactin and cortisol. Small studies tested injections, oral doses and nasal use. Repeated dosing can weaken the GH response. A 16-week study found no significant body-composition benefit. Acute heart effects do not establish treatment benefit or safety for chronic use.

• In small studies, it raised growth hormone, but the effect weakened with repeated use. (Studied in a trial)
• Small short-term studies found brief changes in heart pumping; lasting heart benefits were not shown. (Studied in a trial)
• In a very small study of children, growth speed stayed above their starting level as the hormone effect faded. (Studied in a trial)

Uses in the sources

• Studied to trigger GH release and explore GH-deficiency testing; this is not an approved treatment schedule. (Studied in a trial) (source)
• Small acute studies examined heart pumping function; lasting heart-disease benefits were not established. (Studied in a trial) (source)
• A 16-week SC study found no significant change in lean mass, body fat or bone density. (Studied in a trial) (source)
• A seven-person nighttime study reduced deep sleep despite raising GH. (Studied in a trial) (source)

Hexarelin dosage

Typical reported dose: 50–200 mcg two or three times a day

• IV dose test: 0.5: 0.5 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV dose test: 1: 1 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• IV dose test: 2: 2 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
• Single SC challenge: 1.5: 1.5 mcg/kg SC once. once per acute test, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)
• Single SC challenge: 3: 3 mcg/kg SC once. once per acute test, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)
• Single nasal challenge: 20 mcg/kg intranasally once. once per acute test, nasal spray. Studied in a trial. Studied in: Adults in the cited study. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Hexarelin

Comes as: Lyophilized powder vial reported online, Controlled IV/SC study preparations, Nasal and oral research formulations.

Mixed with: Community threads mention bacteriostatic water; no approved hexarelin diluent or preparation label was found..

Common vial sizes: 2, 5 mg. Common water amounts: 1, 2 mL.

• Forum water volumes vary; these are observations, not validated mixing instructions.
• The mixing thread contains a mg/mcg error. Do not use that wording to calculate a dose.
• HPLC purity does not establish sterility or endotoxin safety after mixing.

Before mixing: Users report refrigerator or freezer storage. A validated shelf life for community vials was not found.

After mixing: Users report refrigeration; no validated duration, preservative compatibility or repeated-puncture sterility window was found.

Hexarelin side effects and risks

Reported side effects

• Cortisol and prolactin increases: In acute IV tests, prolactin rose up to about 180% and cortisol about 40%; these are changes, not incidence rates., moderate (source)
• Weaker GH response with repeated use: GH AUC fell from 19.1 to 10.5 mcg/L·hour by week 16; recovered after four weeks off., mild (source)
• Reduced deep sleep: Observed in a seven person nighttime experiment; event rate not reported., moderate (source)
• Blood pressure changes: unknown, moderate (source)
• Swelling, joint discomfort or glucose changes: unknown, moderate (source)
• Immune reaction or injection infection: unknown, serious (source)

Stop and get help if

• Trouble breathing, tongue swelling, fainting or widespread hives: Stop and get emergency care now.
• Sudden severe headache, new vision loss or repeated vomiting: Get emergency assessment now; a pituitary or pressure problem must be excluded.
• Chest pain, severe breathlessness or collapse: Call emergency services now.
• Persistent severe abdominal pain or repeated vomiting: Stop and get urgent medical assessment.
• Confusion, seizure, or low blood sugar that does not resolve: Get emergency help now; do not drive.
• Fever with a hot, spreading, painful injection site: Get urgent care for a possible injection infection.

Who should avoid it

• pregnant: Avoid during pregnancy. Reproductive safety is unstudied; this screen is precautionary.
• breastfeeding: Avoid while breastfeeding. Human infant exposure and safety are unknown.
• tryingToConceive: Avoid while trying to conceive. Human fertility and early-pregnancy safety are unknown.
• under18: Historical child studies do not support unsupervised use in minors.
• activeCancer: GH and IGF-1 are growth signals. Avoid with active cancer; this applies GH-treatment precautions to secretagogues.
• cancerHistory: Prior cancer needs a clinician review before raising GH or IGF-1. Recurrence risk with this compound is unknown.
• diabetes: GH-related changes can worsen insulin sensitivity. Review blood sugar control and medicines.
• heartCondition: Fluid retention may strain the heart. Heart-disease safety is not established for home-use schedules.
• uncontrolledBloodPressure: Review uncontrolled blood pressure before use. Fluid retention and pressure changes need assessment.
• kidneyDisease: Kidney-disease dose adjustments and repeated-dose safety are not established.
• liverDisease: Liver-disease dose adjustments and repeated-dose safety are not established.
• diabeticRetinopathy: Review proliferative eye disease before raising GH or IGF-1. This is a GH-class precaution.
• pancreatitisHistory: Review prior pancreatitis. GH-class safety concerns do not establish a risk rate for this compound.
• sleepApnea: Review sleep apnea and new swelling. GH-related tissue or fluid changes are a class concern.
• surgeryPlanned: Tell the surgical team about use and all stacks. Perioperative safety depends on the specific study setting.
• testedAthlete: WADA bans this compound at all times, including out of competition.
• other: Do not add a GH secretagogue when GH or IGF-1 is already excessive. Investigate the cause.
• other: A pituitary mass needs specialist review. GH testing and GH-raising drugs are not interchangeable.

Interactions

• Insulin and sulfonylureas: GH-class precaution: insulin sensitivity and medicine needs can change. Exact interaction trials for this peptide are lacking.
• Other GH secretagogues, GH, and IGF-1: Overlapping GH/IGF-1 effects can add hormone, swelling and blood sugar risks. Combination benefit is not established.
• Glucocorticoids and oral estrogen: These can change GH responses or IGF-1 interpretation. Do not change prescribed hormone replacement to alter a peptide response.
• Anticoagulants and antiplatelets: General injection precaution: blood thinners increase bleeding/bruising risk. A direct interaction with this peptide has not been established.

Product quality risks

• Unregulated products may have the wrong identity, dose or sterility. A purity percentage alone cannot establish injection safety.
• Related GHRPs had altered identities in seized products. No hexarelin-specific market survey was found.
• No representative market-wide contamination or underdosing rate was found for this compound.

What to expect

At least 71 human research papers; some share participants. A small 16-week study found no significant change in body fat or lean mass.

Key studies

• Early IV dose response: The acute GH response approached a plateau while clinical benefits remained untested. (source)
• IV, SC, nasal and oral comparison: Much larger oral and nasal doses were needed to produce a GH response. (source)
• GH, cortisol and prolactin dose response: Hexarelin is not specific to GH release. (source)
• Hexarelin versus GHRP-2: The study does not establish that hexarelin is universally stronger or safer than GHRP-2. (source)
• Two IV doses one or two hours apart: A second injection did not simply reproduce the first hormone pulse. (source)
• Two versus three SC doses in a day: Three injections did not improve the measured 24-hour GH effect over two. (source)

Hexarelin FAQ

• Is Hexarelin FDA-approved? No FDA-approved product or dose label found; no approval for physique or performance use.
• How do people take it? Under the skin, two or three times daily. Source: reported by users, not an established dose.
• What's the difference between Hexarelin and Ipamorelin? Hexarelin: a peptide that releases growth hormone; repeated use can weaken the response. Ipamorelin: an experimental peptide that triggers growth hormone release. Why people pair them: users propose rotating secretagogues after short hexarelin cycles.
• Can I take it with Ipamorelin or GHRP-2 rotation? Users propose rotating secretagogues after short hexarelin cycles. No trial validates rotation to prevent response attenuation or reduce harms. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named on the 2026 list; prohibited in and out of competition.
• How long does a mixed vial last? Users report refrigeration; no validated duration, preservative compatibility or repeated-puncture sterility window was found.